Scruggs, Phouangmala, Siok L. Dun, and Nae J. Dun. Cocaine-and amphetamine-regulated transcript peptide attenuates phenylephrine-induced bradycardia in anesthetized rats.
BAROREFLEX, which serves a crucial role in homeostasis and maintenance of arterial pressure and heart rate (HR), is the first line of defense against changes in blood pressure (BP). When baroreceptors are stretched, signals are sent to the central nervous system via the vagus (X) or glossopharyngeal (IX) nerves (2) . Afferents from both nodose and petrosal ganglia enter the medulla oblongata dorsolaterally and project to secondorder neurons in the nucleus tractus solitarius (NTS) where the signals are integrated and processed. Glutamate or a closely related amino acid is thought to be the principal neurotransmitter released on baroreflex stimulation (23) . In addition, neuropeptides, including calcitonin gene-related peptide, cholecystokinin, enkephalin, galanin, neuropeptide Y, neurokinin A, neurokinin B, somatostatin, substance P, and vasoactive intestinal polypeptide, have been localized to neurons of the nodose and petrosal ganglia (25) . More recent studies have shown that oxytocin is detectable in the nodose ganglion and may serve as a neurotransmitter to the vasomotor center (12) .
Cocaine-and amphetamine-regulated transcript (CART) was first identified by PCR-differential display in the striatum after acute administration of cocaine and amphetamine to the rats (7) . The CART cDNA encodes a peptide of either 129 or 116 amino acid residues in length, with a predicted leader sequence of 27 amino acids, resulting in two mature peptides of either 102 (long form) or 89 (short form) amino acid residues (7). The rat expresses both the long and short forms, whereas the human expresses only the short form (7) . The preproCART contains several pairs of basic amino acids at positions 28-29, 48-49, 53-54, 60-61, and 77-78, suggesting that the peptide is processed into several smaller fragments (7) . In Western blot studies, six different CART peptides varying from 4 to 14 kDa have been detected in rat tissues; these include CART and CART 62-102 of the long form (16) . Functional studies indicate that CART 55-102 is biologically active, as it potently inhibits feeding when injected intracerebroventricularly to the rats (1) or sensitizes thermal pain-induced hindpaw withdrawal (19) . Furthermore, immunohistochemical studies show that antiserum directed against the CART 55-102 robustly labeled neurons in the hypothalamus, brain stem, spinal cord, pituitary, and autonomic nerves, supporting the contention that CART 55-102 is present endogenously (8) (9) (10) . For this reason, CART 55-102 , which is referred to herein as CARTp, was used in this study.
Immunohistochemical and in situ hybridization studies reveal an extensive distribution of CART peptide in the central and peripheral nervous system of the rat (4, 14) . A particularly dense plexus of CARTimmunoreactive (irCART) fibers is noted in the NTS (9, 10, 14) . The present study was undertaken to evaluate the hypothesis that CARTp, which may be released from vagal afferents, modulates baroreflex in anesthetized rats. Immunohistochemistry and tract-tracing experiments were conducted to identify the location of cell bodies that may give rise to irCART fibers observed in the NTS.
METHODS AND MATERIALS
Animal protocols. A breeding colony of Sprague-Dawley rats (Harlan, Indianapolis, IN) was established at the Division of Laboratory Animal Resources, East Tennessee State University. Animals were maintained at 22 Ϯ 1 C with an alternating 12:12-h light-dark cycle. Food and water were available ad libitum. Animal protocols were reviewed and approved by the Institutional Animal Care and Use Committee. Male Sprague-Dawley rats, weighing 275-350 g, were anesthetized with urethane (1.2 g/kg ip). The depth of anesthesia was monitored by observing responses to pinching the tail. Rectal temperature was maintained at 37 Ϯ 1°C with the use of a thermoblanket. The right femoral artery was cannulated with a polyethylene tubing (Intramedic PE-50) and connected to a pressure transducer with its output to a Gould pen recorder. The BP signal was used to trigger a Biotach amplifier (Gould ECG/BiTac') for HR recording. The right femoral vein was cannulated with a polyethylene tubing for intravenous injection of phenylephrine (PE; 7-10 g/kg). The depth of anesthesia was subsequently maintained by intravenous administration of urethane after cannulation of the femoral vein. Urethane (30-60 mg/kg) was given as needed, usually every 1.5-2 h. All intravenous injections were conducted via a 1 ml tuberculin syringe mounted on an infusion pump (KD Scientific, New Hope, PA) at a rate of 3.5 l/s. Data were analyzed statistically using either the Kruskal-Wallis statistics followed by Dunn's post test or the Student's t-test, with P Ͻ 0.05 considered statistically significant. Results are expressed as means Ϯ SE.
Intracisternal injections. Rats were placed in a stereotaxic frame (David Kopf, Tujunga, CA) with the bite bar 13 mm below the interaural line. An incision was made at the top of the head to expose the dorsal neck muscles. The atlantooccipital membrane and occipital bone were exposed by using a spatula to scrape away the dorsal neck muscles. A microinjection needle, connected to a 10-l syringe (Hamilton, Reno, NV) via polyethylene tubing (Intramedic PE-10), was attached to the stereotaxic apparatus. The ␣-adrenergic agonist PE was injected intravenously at least twice, 10 min apart, to elicit a control baroreflex response before intracisternal injection of CARTp or CART antiserum was to begin. Intracisternal injections of CARTp were given at a fixed volume of 4 l at the concentrations of 0.1, 0.3, 1, and 3 nmol over a period of 5 s. Subsequent injections of PE were administered every 10 min for 70 min to monitor the effects of CARTp on PE-induced baroreceptor reflex. Each rat received one dose of CARTp.
NTS microinjections. The atlanto-occipital membrane and occipital bone were exposed as previously indicated. A drill was used to remove part of the occipital bone. The dura and atlanto-occipital membranes were then removed with iris scissors to expose the medulla and cerebellum. Using an automatic nanoliter injector (Drummond Scientific, Broomall, PA), injections were made to the NTS at the following coordinates: 0.5 mm rostral to the calamus scriptorius, 0.5 mm lateral to the midline, and 0.5 mm deep from the dorsal medullary surface. Injections of L-glutamate (0.5 mM) in a volume of 50 nl were made to functionally identify the NTS coordinates before CARTp or CART antiserum injection. The experiment continued only if glutamate induced a depressor and bradycardic effect (6, 24) . Rats were injected either with CARTp (n ϭ 20), CART antiserum (n ϭ 5), normal rabbit serum (NRS) (n ϭ 5), saline (n ϭ 5), or CARTp with CART antiserum (n ϭ 5). All injections were made at a volume of 50 nl to each side of NTS. Before NTS injections were made, PE was administered at least twice to elicit a control baroreflex response. Subsequent injections of PE were administered every 10 min for 70 min.
Injection sites were marked by injecting diluted India ink (50 nl) at the end of each experiment. Brains were removed, fixed in 4% paraformaldehyde, and immersed in 30% sucrose overnight. Brain stems were cut into 50-m sections, mounted on glass slides, and stained with Cresyl violet. Injection sites were then viewed under a microscope and verified with a standard atlas (21) .
Immunohistochemical studies. Rats were anesthetized with urethane (1.7 g/kg ip) and intracardially perfused with PBS followed by 4% paraformaldehyde in PBS. Brain stems and nodose ganglia were removed and postfixed in the same fixative for 2 h followed by immersion into 30% sucrose in PBS overnight. Brain stems were embedded in agar and then cut into 50-m coronal sections using a vibratome. Nodose ganglia were embedded and frozen in Tissue Tek OCT compound (Pella, Redding, CA) and cut into 50-m sections with a cryostat (International Equipment, Needham, MA). Tissue, which was collected as free floating sections, was thoroughly washed with PBS, blocked with normal goat serum (1:10) for 2 h, and followed by incubation with CART antiserum (1: 1,500) for 2 days. Normal goat serum and CART antiserum were diluted with 0.4% Triton X-100 and 0.5% BSA in PBS. Tissues were washed with PBS before incubation with biotinylated anti-rabbit IgG (1:50) for 2 h and washed again before incubation with avidin fluorescein isothiocyanate (FITC) (1:50) for 3 h. Tissues were mounted on gelatin-coated glass slides, and Citifluor mountant media (Pella) was applied before coverslipped.
Retrograde tracing studies. Rats were anesthetized with intraperitoneal injection of urethane (0.6 g/kg), ketamine (50 mg/kg), and xylazine (12 mg/kg). Ketamine was injected first, followed by xylazine and then urethane. Rats were then placed in a stereotaxic apparatus where the dorsal medulla was exposed as previously described. A glass micropipette (tip diameter ϭ 20-40 m) connected to the automatic nanoliter injector was used for unilateral injection of 1% Fluorogold in a volume of 50 nl. The micropipette was introduced into the dorsal medulla at least 5 min before injection and left in the medulla at least 5 min after injection. Site of injection was 0.5 mm rostral to calamus scriptorius, 0.5 mm lateral to midline, and 0.5 mm deep from the dorsal surface of the medulla. The incision was closed, and animals were allowed to recover from anesthesia. All procedures were performed in aseptic conditions. Animals were given a subcutaneous injection of buprenorphine (0.2 mg/kg) before recovery to reduce pain and discomfort.
After 72 h, rats were reanesthetized with urethane and intracardially perfused with PBS followed by 4% paraformaldehyde. Brains were removed, fixed, and sectioned as previously described. Brain stem sections were viewed as freefloating sections under a microscope for verification of injection site. Injections sites were taken as a tract in the tissue made by the micropipette. The damaged sites were easily identified due to the presence of residual blood even after the animal was flushed with PBS and paraformaldehyde. Tissues were then processed for immunohistochemistry and double-stained for CART and Fluorogold immunoreactivity using FITC and Texas red, respectively. Double-labeling procedures are as follows. Tissues were processed as previously described. Following the completion of CART immunostaining, tissues were thoroughly washed with PBS and incubated with the second primary antiserum, i.e., Fluorogold antiserum, for 2 days. Tissues were washed with PBS, incubated with biotinylated anti-rabbit IgG (1:50), washed with PBS, incubated with avidin Texas red (1:50) for 3 h, and mounted. Fluorogold antiserum was used at a dilution of 1:3,000 with 0.4% Triton X-100 and 0.5% BSA in PBS. Sections were examined under a laser confocal microscope (Leica TCS SP2). The excitation and emission wavelengths were set to 488/543 nm for FITC and 520/620 nm for Texas red.
Chemicals and reagents. CART peptide (CART 55-102) was from American Peptide (Sunnyvale, CA). CART antiserum was a gift from Dr. J. K. Chang, Phoenix Pharmaceuticals (Belmont, CA), and normal rabbit serum albumin was from Vector Laboratories (Burlingame, CA). All other chemicals were from Sigma (St. Louis, MO). 
RESULTS
CART immunoreactivity in the medulla oblongata and nodose ganglia. As reported earlier (9, 14) , CART immunoreactivity (irCART) was observed in a dense plexus of cell processes throughout the NTS and dorsal motor nucleus of the vagus; fibers were also noted in the area postrema (Fig. 1, A and B) . Few irCART somata were detected in these areas. With respect to nodose ganglia, numerous irCART neurons and varicose fibers were noted throughout the ganglion (Fig. 1,  C and D) . Labeled ganglion cells were predominantly spherical and measured 10-30 m in diameter (Fig. 1,  C and D) .
irCART nodose ganglion cells project to the NTS. To determine whether irCART fibers observed in the NTS originate from neurons in the nodose ganglion, Fluorogold was unilaterally injected into the NTS 3 days before the terminal experiment. Nodose ganglion sections double-labeled with CART and Fluorogold antisera showed numerous nodose ganglion cells expressing CART and Fluorogold immunoreactivity (Fig. 2) . These neurons were noticeably smaller than those neurons that were labeled only with CART or Fluorogold (Fig. 2) . The number of cells containing both irCART and Fluorogold was visually counted. Approximately 80% of neurons in the nodose ganglion expressed Fluorogold. Of those that contained Fluorogold, 64% were irCART, indicating that ϳ54% of the cells in the nodose ganglion are irCART and may project to the NTS.
Intracisternal administration of CARTp attenuates PE-induced bradycardia. The mean MAP and HR in urethane-anesthetized rats were 103 Ϯ 2 mmHg and 368 Ϯ 6 beats/min (n ϭ 20). CARTp was administered in four doses: 0.1, 0.3, 1, and 3 nmol, in a volume of 4 l by intracisternal injection. Each rat received one dose of CARTp (0.1-3 nmol). Administration of CARTp did not cause a significant change in either the basal HR or MAP (Fig. 3) . However, CARTp consistently and dose dependently attenuated the PE-induced bradycardia, as assessed by the decrease in baroreflex gain (Fig. 4A) . The effect of CARTp reached its peak ϳ10 min after injection and dissipated in the ensuing 10-20 min.
Intra-NTS administration of CARTp attenuates PEinduced bradycardia. To assess whether the attenuation of PE-induced bradycardia occurred within the NTS, CARTp was administered bilaterally into the NTS. Figure 5 shows the schematic diagram of a transverse section of medulla oblongata, as adapted from the atlas of Paxinos and Watson (21), where the injection sites were marked by India ink. The mean MAP and HR in urethane-anesthetized rats in this set of experiments were 104 Ϯ 2 mmHg and 350 Ϯ 5 beats/ min (n ϭ 20). CARTp was given at doses of 0.1, 0.3, 1, and 3 nmol in 50 nl unilaterally (or 100 nl bilaterally). CARTp consistently and dose dependently attenuated the PE-induced bradycardia (Fig. 4B) .
CART antiserum potentiates PE-induced bradycardia. Because specific CART receptor antagonists are currently not available, we used CART antiserum to evaluate the specificity of the effects observed after CARTp administration. CART antiserum is a rabbit polyclonal directed against the active fragment CART 55-102 (8) (9) (10) . The antiserum exhibits 100% cross-reactivity with the rat CART 55-102 (8) . CART antiserum (1:500) was injected bilaterally into the NTS. Administration of CART antiserum to the NTS produced no significant changes in basal MAP or HR (Fig. 6A) . The antiserum potentiated the bradycardia induced by PE but did not significantly alter the PEinduced MAP changes (Fig. 6A) . PE produced an average increase of 64 Ϯ 4 mmHg in MAP and a decrease of Ϫ77 Ϯ 3 beats/min in HR (n ϭ 5) before and 62 Ϯ 3 mmHg and Ϫ96 Ϯ 12 beats/min after CART antiserum.
Administration of CARTp with CART antiserum, normal rabbit serum, and saline. To assess the specificity of CART antiserum, CARTp (0.3 nmol) and CART antiserum (1:500) were coadministered to the NTS. Administration of CARTp and CART antiserum did not produce any significant changes in basal MAP or HR nor did it produce any significant changes in PE-induced baroreflex response (Fig. 6C) . Similarly, injection of physiological saline or normal rabbit serum (1:500) to the NTS did not cause any significant changes in resting MAP or HR or in the PE-induced baroreflex (Fig. 6, B and D, respectively) . Results from five rats assigned to each series of experiments are shown in Fig. 7 .
DISCUSSION
The major observation made in this study is that a subset of neurons in the nodose ganglion may give rise to a dense plexus of irCART fibers in the NTS and that CARTp administered intracisternally or directly into the NTS attenuated PE-induced bradycardia, whereas CART antiserum injected into the NTS potentiated PE-induced bradycardia.
It is well established that vagal afferents project to the NTS and that the NTS is the predominant site of autonomic cardiovascular control. Lesions or other perturbations to the NTS result in increased arterial pressure (11, 22) . Previous immunohistochemical and in situ hybridization studies show that irCART is present in fibers of the NTS and in neurons of the vagal nerves, respectively (3, 9, 14) . Our immunohistochemical results confirm the presence of a dense plexus of irCART fibers throughout the rostrocaudal axis of the NTS. Although the possibility that irCART fibers observed in the NTS may be derived from other sources cannot be excluded, retrograde tract-tracing studies demonstrate that some of the irCART fibers in the NTS arise from neurons in the nodose ganglion. In our study, ϳ50% of nodose ganglion cells that are Fluorogold positive are also irCART, which is consistent with a previous report that ϳ50% of vagal afferents are irCART (3). More interestingly, irCART nodose ganglion cells are generally of smaller diameter compared with Fluorogold and/or CART-negative nodose neurons. Because of their small size, irCART nodose neurons that project to the NTS may belong to the slowly conducting type C neurons. It is pertinent to mention that not all nodose ganglion cells projecting to the NTS are baroreceptor afferents. Hence, not all irCART nodose ganglion cells projecting to the NTS are baroreceptor related.
Intracisternal injection of CARTp consistently attenuated PE-induced bradycardia in a dose-dependent manner. CARTp injected intracisternally may reach a number of sites in the dorsal medulla that could potentially alter the cardiovascular response. To assess the role of NTS in relation to the action of CARTp, the peptide was injected directly into an area of NTS that is thought to be the predominant site of baroreceptor afferent termination (24) . CARTp injected into the NTS attenuated the PE-induced bradycardia in a dosedependent manner as well, suggesting that CARTp acts at the level of NTS. Our finding does not necessarily exclude the possibility that CARTp may act on other sites in the dorsal medulla to alter cardiovascular responses. Matsumura et al. (18) reported that CARTp by intracerebroventricular injection increased MAP, HR, and renal sympathetic nerve activity (RSNA) in conscious rabbits. Intracisternal or intra-NTS administration of CARTp in the concentrations used in our study did not cause a significant change in basal arterial pressure or HR in anesthetized rats. Differences in experimental species and sites of administration as well as the observed time frame may have accounted for this discrepancy. Elevation of MAP and RSNA was observed 30-40 min and increase of HR was observed ϳ90 min after CARTp administration in rabbits, whereas in this study, the effect of CARTp reached its peak ϳ10 min after injection in rats. Furthermore, CARTp was injected intracerebroventricularly, which may activate supramedullary neurons, leading to a different profile of cardiovascular responses in the case of rabbits.
CARTp receptor antagonists are currently not available. CART antiserum, a rabbit polyclonal directed against the biologically active fragment CART 55-102 (8) (9) (10) , was employed here to evaluate the pharmacological specificity of the effects of CARTp. Intra-NTS injections of CART antiserum augmented PE-induced bradycardia but did not produce a significant change in basal MAP or HR. If CARTp were tonically released, one would expect to see changes in baseline MAP and HR after CART antiserum. Because there were no significant changes in baseline activity, the peptide may not be tonically released under current experimental conditions. Alternatively, the lack of effect may indicate that the quantity of CARTp being released under basal conditions is negligible. Intra-NTS injections of physiological saline, normal rabbit serum, and concomitant injection of CARTp and CART antiserum did not produce any significant changes in baseline MAP and HR or in PE-induced bradycardia. The ineffectiveness of CARTp and CART antiserum when injected simultaneously to the NTS further attests to the specificity of CART antiserum. More importantly, CART antiserum augmented the PE-induced bradycardia, implying CARTp is released in a quantity sufficiently large to produce a significant damping effect on medullary outflow to the heart during PE-induced baroreflex. As a corollary, CART antiserum may augment PE-induced bradycardia by disinhibition.
Perspectives
CART-containing neurons and cell processes are widely distributed in the forebrain, hindbrain, spinal cord, peripheral autonomic ganglia, and adrenal medulla (8, 14) . Information relative to the pathwayspecific function of this peptide is relatively sparse. CARTp injected intracerebroventricularly attenuates feeding, as assessed by food consumption in rats (1, 15, 17) . Intracisternal, but not intravenous, injection of CARTp inhibits gastric emptying (20) . Other studies have shown that CARTp by intravenous administration increases amylase secretion from the rat pancreas (5) . CARTp when injected intrategmentally increases locomotor activity in rats (13) . Because CARTp is injected either intravenously or intracerebroventricularly, it is not possible to establish a direct correlation between function and pathway in these studies. Viewed in this context, our finding provides the first evidence of a pathway-specific function of CARTp.
